Autonomix Medical, Inc. to Present at Investment Conference
Autonomix Medical, Inc. (NASDAQ: AMIX), a prominent player in the medical device sector, is preparing to present at the H.C. Wainwright 26th Annual Global Investment Conference. This important event will be held in New York and will spotlight emerging technologies within the medical industry.
Conference Presentation Details
Brad Hauser, the Chief Executive Officer of Autonomix, will showcase the company's groundbreaking platforms that aim to revolutionize the diagnosis and treatment of nervous system-related diseases. Scheduled for September 9-11, 2024, the conference seeks to connect companies with investors, providing a forum for discussions about the future of medical technologies.
One-on-One Meetings
Alongside the main presentation, the management team will participate in one-on-one meetings with registered investors during the conference. These sessions offer a valuable chance for investors to explore Autonomix’s innovative projects and business strategies in greater detail. Interested individuals are encouraged to register for the event to secure their opportunity for personalized discussions.
Accessing the Presentation and Webcast
A video webcast of the presentation will be available for on-demand viewing starting September 9, 2024. This feature enables investors who cannot attend the conference in person to access vital information about Autonomix’s advancements and future initiatives. The webcast will be hosted on the company’s investor relations page, ensuring easy access for all stakeholders.
Company Overview
Autonomix Medical, Inc. is committed to advancing medical device technologies that offer unprecedented insights into disorders of the nervous system. Their flagship product is a catheter-based microchip sensing array, which represents a significant advancement in the detection and differentiation of neural signals. With remarkable sensitivity that surpasses existing technologies, Autonomix is leading the charge in developing innovative diagnostic and treatment methods.
Focus on Pain Management
Currently, Autonomix is prioritizing the development of pain management technologies. Their clinical trials are primarily focused on pancreatic cancer, a condition known for causing intense pain and lacking effective treatment options. This emphasis reflects Autonomix's dedication to tackling complex medical challenges where timely solutions are critically needed.
Expanding Treatment Indications
While the current trials are centered on pancreatic cancer, Autonomix is strategically preparing to address a range of medical indications. This includes conditions related to cardiology, hypertension, and chronic pain management, highlighting the versatile potential of their technology. This comprehensive approach not only supports the company's growth trajectory but also aims to improve countless lives by delivering innovative medical solutions.
Investigational Nature of Technology
It is important to recognize that the technology developed by Autonomix is still investigational and has not yet received marketing clearance in the United States. The ongoing research and clinical trials indicate a promising future where their advanced technologies could set new standards in treatment practices.
Contact and Additional Information
For more information about Autonomix and its innovations, please visit autonomix.com. The company actively engages with its audience through various platforms, including X, LinkedIn, Instagram, and Facebook, to enhance accessibility and communication with stakeholders.
Investor and Media Contact
For investor inquiries, please reach out to the JTC Team, LLC, with Jenene Thomas at 833-475-8247 or via email at autonomix@jtcir.com.
Frequently Asked Questions
What is Autonomix Medical, Inc. focused on?
Autonomix Medical, Inc. is focused on advancing innovative medical technologies to revolutionize the diagnosis and treatment of nervous system diseases.
Who will present at the H.C. Wainwright conference?
Brad Hauser, the Chief Executive Officer of Autonomix, will be the presenter at the H.C. Wainwright conference.
What is the primary technology developed by Autonomix?
The primary technology is a catheter-based microchip sensing array designed to detect and differentiate neural signals with high sensitivity.
What medical conditions is Autonomix targeting initially?
Autonomix is initially targeting pain management, with a focus on pancreatic cancer during its initial trials.
How can investors access the presentation?
Investors can access the presentation via a video webcast that will be available on the company’s investor relations page starting from September 9, 2024.
